Clinical Trials
16 trialsNCT02519348 2026-06-03
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT07391670 2026-05-15
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT06117891 2026-05-12
REFINE-IO
Bayer
Active not recruiting
NCT07081633 2026-05-12
TREMENDOUS-2
AstraZeneca
Phase 2 Active not recruiting
NCT06921785 2026-05-11
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT05883644 2026-04-30
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT06109272 2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3 Recruiting
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT01938612 2021-03-12
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00313794 2012-06-07
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
AstraZeneca
Phase 2 Completed
NCT00556023 2012-06-06
A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer
AstraZeneca
Phase 1 Completed